Answers are grounded in this paper and cite their sources.
Demonstrates extended overall survival and fewer severe adverse events with nivolumab in advanced renal-cell carcinoma, indicating superior therapeutic benefit.
Among patients with previously treated advanced renal-cell carcinoma, overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus. (Funded by Bristol-Myers Squibb; CheckMate 025 ClinicalTrials.gov number, NCT01668784.).
No takes yet. Share an insight, caveat, or question.
Motzer et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: